Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects for the Development of Cellular Immunotherapy Product
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy Subject
- Sponsor
- Jun Zhu
- Enrollment
- 172
- Locations
- 1
- Primary Endpoint
- Collect blood samples
- Last Updated
- 4 years ago
Overview
Brief Summary
Title: Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy Subjects for the Development of Cellular Immunotherapy Product
Background:
CAR-T therapies are being developed that utilize modified immune cells to fight tumors. 'Off-the-shelf' allogeneic CAR-T technology has better efficacy and more promising clinical applications. Investigators want to use the cells of healthy subjects to perform the studies. To accomplish this, they are collecting PBMCs through apheresis.
Objectives:
To collect PBMCs from healthy subjects for product development for cell Immunotherapies.
Detailed Description
Background: Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells from donors has many potential advantages over autologous approaches, such as the immediate availability of cryopreserved batches for patient treatment, possible standardization of the CAR-T cell product, time for multiple cell modifications, redosing or combination of CAR T cells directed against different targets, and decreased cost using an industrialized process. The T cells currently used for CAR-T cell manufacturing are mainly derived from peripheral blood mono-nuclear cells (PBMCs) .The manufacture of allogeneic CAR T cells from PBMCs collected from healthy donors is associated with the ability to make multiple vials from a single apheresis product. Allogeneic CAR T cells are created from healthy donors, they are generated from immune cells that have not been impacted by the immune effects of cancer or by exposure to chemotherapeutic agents, in contrast to autologous T cells from patients. The selection of donors on the basis of their immune characteristics is likely to be a key factor in decreasing the heterogeneity of the final cell product Objectives: * To produce allogeneic CAR T cells with different targets and other cell products by using PBMCs from healthy subjects. * To develop and optimize the methodology for the response or quality determination of cell Immunotherapy products. Design: All subjects are required to sign a written informed consent form for the study. After the signing of informed consent form, participants will be screened with a series of vital signs, physical examinations and laboratory tests. Demographic data and medical history of the subjects will also be documented. In addition, 30 mL peripheral venous blood sample will be collected to evaluate the biological characteristics of each subject. Participants will undergo a routine blood test within 24 hours before the apheresis to reconfirm their eligibility and 3-5 mL blood samples are to be drawn for the development of detection methods of cell-based immunotherapy. Subjects who meet all the inclusion criteria and do not meet any exclusion criteria are qualified to donate peripheral blood mono-nuclear cells (PBMCs) by means of apheresis. 6×10\[9\] of cells for each healthy person are preferred. 172 healthy subjects are to be enrolled through the whole study.
Investigators
Jun Zhu
Chief Physician
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
Eligibility Criteria
Inclusion Criteria
- •18 to 40 years of age
- •Male≥50 kg, female≥45 kg with 18.5≤ BMI ≤30
- •Subject has provided informed consent
Exclusion Criteria
- •Subject has respiratory diseases, circulatory system diseases, digestive system diseases, urinary system diseases, hematological system diseases, autoimmune diseases, endocrine disorders or metabolic disorders;
- •Subject has nervous system diseases, mental illness, Creutzfeldt-Jakob disease or those with a family history, or those treated with tissue or tissue derivatives that may be derived from Creutzfeldt-Jakob infected people;
- •Subject has chronic skin diseases, especially infectious, allergic or inflammatory systemic skin diseases;
- •Subject has allergic diseases or recurrent allergies;
- •Malignant tumors or health-affecting benign tumors;
- •Twice or more times of blood pressure measurement exhibit (except for white coat hypertension): systolic blood pressure \< 90 or ≥ 140 Millimeter of mercury (mm Hg), or diastolic blood pressure \< 60 or ≥ 90 mm Hg, or pulse pressure \< 30 mm Hg, heart rate: \< 60 beats/min or \>100 beats/min;
- •Laboratory tests: hemoglobin: male \<120 g/L, female \<115 g/L, or liver and kidney laboratory result \>1.5x upper limit of normal with clinical significant, or abnormal12-lead ECG with clinical significant, or abnormal abdominal B-mode ultrasound with clinical significant, or abnormal chest X-ray with clinical significant, and T cell detection of tuberculosis infection is over the limit or positive;
- •Abnormal lymphocyte subset panel test result with clinical significance (Lymphs%, CD3+, CD3+CD4+, CD3+CD8+, CD3-CD16+CD56+,CD19+) ;
- •Hepatitis B surface antigen positive, hepatitis B virus (HBV) DNA positive, hepatitis B e antigen positive, hepatitis C antibody positive, Treponema pallidum antibody positive ,human immunodeficiency virus antibody positive, human T-cell lymphotrophic virus antibody positive, Epstein-Barr virus positive, or COVID-19 nucleic acid positive ;
- •Recipient of organ transplant;
Outcomes
Primary Outcomes
Collect blood samples
Time Frame: 2 years
Collect blood samples (whole blood and PBMC) from healthy subjects for the Development of Cellular Immunotherapy Product.